Cost-effectiveness analysis of HLA-B*13:01 screening for the prevention of co-trimoxazole-induced severe cutaneous adverse reactions among HIV-infected patients in Thailand

References

• Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331(19):1272–1285. doi: 10.1056/NEJM199411103311906.
   PubMed Web of Science ®Google Scholar
• Adler NR, Aung AK, Ergen EN, et al. Recent advances in the understanding of severe cutaneous adverse reactions. Br J Dermatol. 2017;177(5):1234–1247. doi: 10.1111/bjd.15423.
   PubMed Web of Science ®Google Scholar
• Cho Y-T, Chu C-Y. Treatments for severe cutaneous adverse reactions. J Immunol Res. 2017;2017:1503709–1503709. doi: 10.1155/2017/1503709.
   PubMed Web of Science ®Google Scholar
• Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333(24):1600–1607. doi: 10.1056/NEJM199512143332404.
   PubMed Web of Science ®Google Scholar
• Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169(5):1071–1080. doi: 10.1111/bjd.12501.
   PubMed Web of Science ®Google Scholar
• Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. Am J Med. 2011;124(7):588–597. doi: 10.1016/j.amjmed.2011.01.017.
   PubMed Web of Science ®Google Scholar
• Chen YC, Chang CY, Cho YT, et al. Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan. J Am Acad Dermatol. 2013;68(3):459–465. doi: 10.1016/j.jaad.2012.08.009.
   PubMed Web of Science ®Google Scholar
• Lee HY, Walsh SA, Creamer D. Long-term complications of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow-up. Br J Dermatol. 2017;177(4):924–935. doi: 10.1111/bjd.15360.
   PubMed Web of Science ®Google Scholar
• Chung WH, Wang CW, Dao RL. Severe cutaneous adverse drug reactions. J Dermatol. 2016;43(7):758–766. doi: 10.1111/1346-8138.13430.
   PubMed Web of Science ®Google Scholar
• Mullan KA, Anderson A, Illing PT, et al. HLA-associated antiepileptic drug-induced cutaneous adverse reactions. HLA. 2019;93(6):417–435. doi: 10.1111/tan.13530.
   PubMed Web of Science ®Google Scholar
• Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A. 2005;102(11):4134–4139. doi: 10.1073/pnas.0409500102.
   PubMed Web of Science ®Google Scholar
• Yang SC, Chen CB, Lin MY, et al. Genetics of severe cutaneous adverse reactions. Front Med (Lausanne). 2021;8:652091. doi: 10.3389/fmed.2021.652091.
   PubMed Web of Science ®Google Scholar
• Chen CB, Hsiao YH, Wu T, et al. Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in asians. Neurology. 2017;88(1):78–86. doi: 10.1212/WNL.0000000000003453.
   PubMed Web of Science ®Google Scholar
• Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128(1):35–44. doi: 10.1038/sj.jid.5701033.
   PubMed Web of Science ®Google Scholar
• Bureau of AIDS Tuberculosis and Sexually Transmitted Infection. Thailand national guidelines on HIV/AIDS diagnosis. Treatment and Prevention 2021/2022. 2022.
   Google Scholar
• Sukasem C, Pratoomwun J, Satapornpong P, et al. Genetic association of Co-Trimoxazole-Induced severe cutaneous adverse reactions is Phenotype-Specific: HLA class I genotypes and haplotypes. Clin Pharmacol Ther. 2020;108(5):1078–1089. doi: 10.1002/cpt.1915.
   PubMed Web of Science ®Google Scholar
• Wang CW, Tassaneeyakul W, Chen CB, et al. Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in asians. J Allergy Clin Immunol. 2021;147(4):1402–1412. doi: 10.1016/j.jaci.2020.08.003.
   PubMed Web of Science ®Google Scholar
• Tempark T, John S, Rerknimitr P, et al. Drug-Induced severe cutaneous adverse reactions: insights into clinical presentation, immunopathogenesis, diagnostic methods, treatment, and pharmacogenomics [review. Front Pharmacol. 2022;13:832048. doi: 10.3389/fphar.2022.832048.
   PubMed Web of Science ®Google Scholar
• Satapornpong P, Jinda P, Jantararoungtong T, et al. Genetic diversity of HLA class I and class II alleles in thai populations: contribution to Genotype-Guided therapeutics. Front Pharmacol. 2020;11:78. doi: 10.3389/fphar.2020.00078.
   PubMed Web of Science ®Google Scholar
• Saokaew S, Tassaneeyakul W, Maenthaisong R, et al. Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS/TEN in thai population. PLoS One. 2014;9(4):e94294. doi: 10.1371/journal.pone.0094294.
   PubMed Web of Science ®Google Scholar
• Rattanavipapong W, Koopitakkajorn T, Praditsitthikorn N, et al. Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand. Epilepsia. 2013;54(9):1628–1638. doi: 10.1111/epi.12325.
   PubMed Web of Science ®Google Scholar
• Leelahavarong P, Doungthipsirikul S, Kumluang S, et al. Health technology assessment in Thailand: institutionalization and contribution to healthcare decision making: review of literature. Int J Technol Assess Health Care. 2019;35(6):467–473. doi: 10.1017/S0266462319000321.
   PubMed Web of Science ®Google Scholar
• Tantivess S. Policy making and roles of health technology assessment. J Med Assoc Thai. 2008;91 Suppl 2(Suppl 2):S88–S99.
   PubMedGoogle Scholar
• Husereau D, Drummond M, Augustovski F, et al. Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Value Health. 2022;25(1):3–9. doi: 10.1016/j.jval.2021.11.1351.
   PubMed Web of Science ®Google Scholar
• Chaikledkaew U, Kittrongsiri K. Guidelines for health technology assessment in Thailand (second edition)–the development process. J Med Assoc Thai. 2014;97(Suppl 5):S4–S9.
   PubMedGoogle Scholar
• Konyoung P, Nakkam N, Khawsuk H, et al. Severe cutaneous adverse drug reactions: a study of 219 patients from udon thani hospital. Thai J Pharmacol. 2020;42(1):5–19.
   Google Scholar
• Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. 2022. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf.
   Google Scholar
• Satapornpong P, Pratoomwun J, Rerknimitr P, et al. HLA-B*13: 01 is a predictive marker of Dapsone-Induced severe cutaneous adverse reactions in thai patients. Front Immunol. 2021;12:661135. doi: 10.3389/fimmu.2021.661135.
   PubMed Web of Science ®Google Scholar
• Yip LW, Thong BY, Lim J, et al. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an asian series. Allergy. 2007;62(5):527–531. doi: 10.1111/j.1398-9995.2006.01295.x.
   PubMed Web of Science ®Google Scholar
• Limkobpaiboon S, Dhana N, Jongjarearnprasert K. Prevalence and mortality rate of severe cutaneous adverse reactions at siriraj hospital. Chula Med J. 2010;54(5):468–477.
   Google Scholar
• Immucor Transplant Diagnostic Inc. Lifecodes®hla-sso typing kits. [product insert]. 2015.
   Google Scholar
• Roux A, Canet E, Valade S, et al. Pneumocystis jirovecii pneumonia in patients with or without AIDS, France. Emerg Infect Dis. 2014;20(9):1490–1497. doi: 10.3201/eid2009.131668.
   PubMed Web of Science ®Google Scholar
• Jung IY, Rupasinghe D, Woolley I, et al. Trends in mortality among ART-treated HIV-infected adults in the Asia-Pacific region between 1999 and 2017: results from the TREAT asia HIV observational database (TAHOD) and Australian HIV observational database (AHOD) of IeDEA Asia-Pacific. J Int AIDS Soc. 2019;22(1):e25219.
   PubMed Web of Science ®Google Scholar
• Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. New York (NY): Oxford University Press; 2006.
   Google Scholar
• Department of Medical Sciences MoPH. Service fee for analysis and service. 2023. [cited 2023 June 23]. Available from: https://www3.dmsc.moph.go.th.
   Google Scholar
• Drug and Medical Supply Information Center. Announcement of national drug cost year. 2020. Available from: http://dmsic.moph.go.th/index/dataservice/97/0.
   Google Scholar
• Ministry of Public Health Network of Unit Cost. Unit cost manual for hospital. Nonthaburi, Thailand: MUCC; 2011.
   Google Scholar
• Boettiger DC, Newall AT, Chattranukulchai P, et al. Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost-effectiveness analysis. J Int AIDS Soc. 2020;23 Suppl 1(Suppl 1):e25494.
   PubMedGoogle Scholar
• Riewpaiboon A. Standard cost lists for health economic evaluation in Thailand. J Med Assoc Thai. 2014;97 Suppl 5(Suppl 5):S127–S34.
   PubMedGoogle Scholar
• World Bank. Consumer Price Index 2020. 2021. Available from: https://data.worldbank.org/indicator/FP.CPI.TOTL.
   Google Scholar
• World Bank. Official Exchange Rate 2021. 2021. Available from: https://data.worldbank.org/indicator/PA.NUS.FCRF?locations=TH.
   Google Scholar
• T. W. Health-Related quality of life survey using EQ-5D in 5 diseases: HIV/AIDS, diabetes mellitus, liver cancer, stroke, and injury International Health Policy Program-IHPP; 2016.
   Google Scholar
• Dong D, Sung C, Finkelstein EA. Cost-effectiveness of HLA-B*1502 genotyping in adult patients with newly diagnosed epilepsy in Singapore. Neurology. 2012;79(12):1259–1267. doi: 10.1212/WNL.0b013e31826aac73.
   PubMed Web of Science ®Google Scholar
• Ara R, Brazier J. Comparing EQ-5D scores for comorbid health conditions estimated using 5 different methods. Med Care. 2012;50(5):452–459. doi: 10.1097/MLR.0b013e318234a04a.
   PubMed Web of Science ®Google Scholar
• Buchholz P, Steeds CS, Stern LS, et al. Utility assessment to measure the impact of dry eye disease. Ocul Surf. 2006;4(3):155–161. doi: 10.1016/s1542-0124(12)70043-5.
   PubMed Web of Science ®Google Scholar
• Schiffman RM, Walt JG, Jacobsen G, et al. Utility assessment among patients with dry eye disease. Ophthalmology. 2003;110(7):1412–1419. doi: 10.1016/S0161-6420(03)00462-7.
   PubMed Web of Science ®Google Scholar
• Thavorncharoensap M, Teerawattananon Y, Natanant S, et al. Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter? Clinicoecon Outcomes Res. 2013;5:29–36. doi: 10.2147/CEOR.S38062.
   PubMedGoogle Scholar
• Mallolas J, Zamora L, Gatell JM, et al. Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine. Aids. 1993;7(1):59–64. doi: 10.1097/00002030-199301000-00009.
   PubMed Web of Science ®Google Scholar
• Chang CJ, Chen CB, Hung SI, et al. Pharmacogenetic testing for prevention of severe cutaneous adverse drug reactions. Front Pharmacol. 2020;11:969. doi: 10.3389/fphar.2020.00969.
   PubMed Web of Science ®Google Scholar
• Fernando SL, Broadfoot AJ. Prevention of severe cutaneous adverse drug reactions: the emerging value of pharmacogenetic screening. CMAJ. 2010;182(5):476–480. doi: 10.1503/cmaj.090401.
   PubMed Web of Science ®Google Scholar
• Sukri A, Salleh MZ, Masimirembwa C, et al. A systematic review on the cost effectiveness of pharmacogenomics in developing countries: implementation challenges. Pharmacogenomics J. 2022;22(3):147–159. doi: 10.1038/s41397-022-00272-w.
   PubMed Web of Science ®Google Scholar
• Tassaneeyakul W, Jantararoungtong T, Chen P, et al. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a thai population. Pharmacogenet Genomics. 2009;19(9):704–709. doi: 10.1097/FPC.0b013e328330a3b8.
   PubMed Web of Science ®Google Scholar
• Tassaneeyakul W, Tiamkao S, Jantararoungtong T, et al. Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a thai population. Epilepsia. 2010;51(5):926–930. doi: 10.1111/j.1528-1167.2010.02533.x.
   PubMed Web of Science ®Google Scholar
• Schürmann D, Bergmann F, Albrecht H, et al. Twice-weekly pyrimethamine-sulfadoxine effectively prevents Pneumocystis carinii pneumonia relapse and toxoplasmic encephalitis in patients with AIDS. J Infect. 2001;42(1):8–15. doi: 10.1053/jinf.2000.0772.
   PubMed Web of Science ®Google Scholar
• Schürmann D, Bergmann F, Albrecht H, et al. Effectiveness of twice-weekly pyrimethamine-sulfadoxine as primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmic encephalitis in patients with advanced HIV infection. Eur J Clin Microbiol Infect Dis. 2002;21(5):353–361.
   PubMed Web of Science ®Google Scholar
• Mocroft A, Reiss P, Kirk O, et al. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL? Clin Infect Dis. 2010;51(5):611–619.
   PubMed Web of Science ®Google Scholar
• Weyant RB, Kabbani D, Doucette K, et al. Pneumocystis jirovecii: a review with a focus on prevention and treatment. Expert Opin Pharmacother. 2021;22(12):1579–1592. doi: 10.1080/14656566.2021.1915989.
   PubMed Web of Science ®Google Scholar
• Pinho A, Coutinho I, Gameiro A, et al. Patch testing - a valuable tool for investigating non-immediate cutaneous adverse drug reactions to antibiotics. J Eur Acad Dermatol Venereol. 2017;31(2):280–287. doi: 10.1111/jdv.13796.
   PubMed Web of Science ®Google Scholar
• Friedmann PS, Ardern-Jones M. Patch testing in drug allergy. Curr Opin Allergy Clin Immunol. 2010;10(4):291–296. doi: 10.1097/ACI.0b013e32833aa54d.
   PubMed Web of Science ®Google Scholar
• Romano A, Viola M, Gaeta F, et al. Patch testing in non-immediate drug eruptions. Allergy Asthma Clin Immunol. 2008;4(2):66–74.
   PubMedGoogle Scholar
• Turongkaravee S, Praditsitthikorn N, Ngamprasertchai T, et al. Economic evaluation of Multiple-Pharmacogenes testing for the prevention of adverse drug reactions in people living with HIV. Clinicoecon Outcomes Res. 2022;14:447–463. doi: 10.2147/CEOR.S366906.
   PubMed Web of Science ®Google Scholar